Discussing data from an early safety study, the chief scientific officer of FibroBiologics commented on the benefits of a staggered approach to their clinical research in multiple sclerosis. [WATCH TIME: 5 minutes]
Hamid Khoja, PhD
Advertisement
Chief Scientific Officer, FibroBiologics
Articles by Hamid Khoja, PhD
The chief scientific officer of FibroBiologics discussed the benefits of fibroblast cell technology for this patient population, particularly the absence of adverse effects. [WATCH TIME: 3 minutes]
The chief scientific officer of FibroBiologics spoke on fibroblast cell technology and its specific benefits in comparison stem cell therapy. [WATCH TIME: 4 minutes]
Advertisement
Latest Updated Articles
Assessing Efficacy of Fibroblast Cell Technology in MS and Directing Future Clinical Study: Hamid Khoja, PhDPublished: February 9th 2022 | Updated:
Advertisement
Advertisement
Trending on NeurologyLive - Clinical Neurology News and Neurology Expert Insights
1
Parkinson Agent Tavapadon Shows Continued Efficacy, Safety in Phase 3 TEMPO-4 Trial
2
Elecsys pTau181 Test Cleared, Tividenofusp Alfa PDUFA Pushed Back, Phase 4 LOTUS Study Highlights Real-World Benefit of Trofinetide
3
Bilateral MR-Guided Focused Ultrasound Shows Benefit for Managing Parkinson Motor Complications in Phase 3 Trial
4
Ruptured vs Unruptured Aneurysms: Practical Decision Making with Guilherme Dabus, MD
5
